Initial Low-Dose Dacomitinib for First-Line Treatment of Patients With EGFR Exon 21-Mutated Non-Small-Cell Lung Cancer

Ke-Jun Liu, Lin-Xuan Huang, Guan-Ming Jiang, Ning-Ning Guo, Qing-Lin Tan, Yan-Min Cai, Shi-Yuan Chen, Wei Du, Nian-Xin Fang, Jun Jia · 2026

Read Initial Low-Dose Dacomitinib for First-Line Treatment of Patients With EGFR Exon 21-Mutated Non-Small-Cell Lung Cancer by Ke-Jun Liu, Lin-Xuan Huang, Guan-Ming Jiang, Ning-Ning Guo, Qing-Lin Tan, Yan-Min Cai, Shi-Yuan Chen, Wei Du, Nian-Xin Fang, Jun Jia (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13219808.txt.

Description

Ke-Jun Liu and colleagues test starting lung cancer patients on a low dose of dacomitinib in a 2026 study. Dacomitinib beats older drugs for cancers carrying an EGFR exon 21 mutation, but the forty-five milligram dose causes severe side effects, and many patients cannot stay on it. The question was whether starting low keeps the benefit while trimming the harm.

Thirty-one patients with advanced cancer who began dacomitinib at fifteen or thirty milligrams were compared with thirty-five patients on first-generation EGFR drugs. Tumors shrank in 67.7 percent of the low-dose group, more than in the comparison group, and median time before the cancer progressed reached 14.2 months, favoring dacomitinib. The fifteen and thirty milligram starters fared alike, but severe rash struck a third of the thirty milligram group and nobody on fifteen. The authors present proactive low dosing as a strategy and support for dose-optimization trials.

Catalog record

CREATORKe-Jun Liu, Lin-Xuan Huang, Guan-Ming Jiang, Ning-Ning Guo, Qing-Lin Tan, Yan-Min Cai, Shi-Yuan Chen, Wei Du, Nian-Xin Fang, Jun Jia
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE27 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13219808

Browse the full library · About the Tower of Babel